Cleared Traditional

K932373 - HEMAGEN CARDIOLIPIN ANTIBODY KIT (EIA M...

K932373 is the FDA 510(k) clearance for HEMAGEN CARDIOLIPIN ANTIBODY KIT (EIA M... by Hemagen Diagnostics, Inc.. It is a Class 2 Immunology device (product code MID) cleared through the Traditional 510(k) pathway after a 60-day FDA review.

K932373 · Hemagen Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1993
Decision
60d
Days
Class 2
Risk

K932373 is an FDA 510(k) clearance for the HEMAGEN CARDIOLIPIN ANTIBODY KIT (EIA METHOD0. Classified as System, Test, Anticardiolipin Immunological (product code MID), Class II - Special Controls.

Submitted by Hemagen Diagnostics, Inc. (Waltham, US). The FDA issued a Cleared decision on July 16, 1993 after a review of 60 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Hemagen Diagnostics, Inc. devices

Submission Details

510(k) Number K932373 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 17, 1993
Decision Date July 16, 1993
Days to Decision 60 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
44d faster than avg
Panel avg: 104d · This submission: 60d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code MID System, Test, Anticardiolipin Immunological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MID System, Test, Anticardiolipin Immunological

All 45
Devices cleared under the same product code (MID) and FDA review panel - the closest regulatory comparables to K932373.
SYNELISA CARDIOLIPIN ANTIBODIES
K935288 · Elias U.S.A., Inc. · Jan 1994
ELIAS CARDIOLIPIN IGM ANTIBODIES
K933392 · Elias U.S.A., Inc. · Dec 1993
ELIAS CARDIOLIPIN IGG ANTIBODIES
K933393 · Elias U.S.A., Inc. · Dec 1993
ANTI-CARDIOLIPIN ANTIBODY SCREENING TEST SYSTEM
K932225 · Immuno Concepts, Inc. · Jul 1993
SYNELISA CARDIOLIPIN ANTIBODIES
K924421 · Elias U.S.A., Inc. · Nov 1992
QUANTA LITE(TM) IGA ACA
K922351 · Inova Diagnostics, Inc. · Sep 1992